MARC Record from marc_columbia

LEADER: 05624cam a22003854a 4500
001 6031287
005 20221121225721.0
008 060630t20072007mauaf b 001 0 eng
010 $a 2006021436
016 7 $a101280782$2DNLM
020 $a0763747459 (hardcover : alk. paper)
020 $a9780763747459 (hardcover : alk. paper)
024 3 $a9780763747459
029 1 $aNLM$b101280782
035 $a(OCoLC)ocm70256548
035 $a(NNC)6031287
035 $a6031287
040 $aDNLM/DLC$cDLC$dNLM$dBAKER$dC#P$dOrLoB-B
042 $apcc
050 04 $aRC280.P7$bM65 2007
060 10 $aWJ 762$bR796m 2007
082 00 $a616.99/463$222
245 00 $aMolecular oncology of prostate cancer /$cedited by Jeffrey S. Ross and Christopher S. Foster.
260 $aSudbury, Mass. :$bJones and Bartlett Publishers,$c[2007], ©2007.
300 $aix, 534 pages, 16 pages of plates :$billustrations (some color) ;$c29 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
504 $aIncludes bibliographical references and index.
505 00 $gCh. 1.$tProstate cancer and molecular medicine /$rJeffrey S. Ross and Gennadi V. Glinsky -- $gCh. 2.$tMolecular diagnostic techniques in prostate cancer /$rJeffrey S. Ross -- $gCh. 3.$tMolecular epidemiology of prostate cancer /$rJeffrey S. Ross -- $gCh. 4.$tProstate cancer stem cells /$rJack A. Schalken and Christopher S. Foster -- $gCh. 5.$tProstate cancer screening and chemoprevention /$rJacques Baillargeon, Ian Thompson, Javier Hernandez and David P. Rose -- $gCh. 6.$tMolecular methods, including reverse transcriptase polymerase chain reaction and proteomics, for prostate cancer screening and detection of recurrence and micrometastasis /$rDouglas P. Malinowski -- $gCh. 7.$tGenomic classification of prostate carcinoma /$rWilliam L. Gerald -- $gCh. 8.$tPathology of premalignant lesions and adenocarcinoma of prostate /$rMinxin Che and Wael A. Sakr -- $gCh. 9.$tOverview of prognostic and predictive factors in prostate cancer /$rJeffrey S. Ross, Timothy A. Jennings, Tipu Nazeer, Christine E. Sheehan, Hugh A. G. Fisher, Ronald A. Kauffman and Bhaskar V. S. Kallakury -- $gCh. 10.$tCytogenetics and molecular genetics of prostate cancer /$rArthur R. Brothman, Teresa M. Maxwell, Joseph Pettus and Stanford Putman -- $gCh. 11.$tDNA ploidy and S phase analysis in prostate cancer /$rJeffrey S. Ross, Merrill S. Ross, Metin Punar, Ann B. Boguniewicz, Tipu Nazeer and TImothy A. Jennings -- $gCh. 12.$tCell proliferation markers and cell cycle regulators in prostate cancer /$rJeffrey S. Ross, Scott E. Eggener and Carlos Cordon-Cardo -- $gCh. 13.$tTargeted therapies for cancer : integrating diagnostics and therapeutics /$rJeffrey S. Ross -- $gCh. 14.$tThe androgen receptor and hormone-based therapies /$rKristin A. Raclaw and Donald J. Tindall -- $gCh. 15.$tHER-2 and anti-HER-2 targeted therapies /$rAnjali Jain, Ronal L. Shazer, Isett Laux, Jeffrey S. Ross and David B. Agus -- $gCh. 16.$tEpidermal growth factor receptor and other growth factors and receptors /$rBegona Mellado, Joan Carles, Jeffrey S. Ross and Joan Albanell -- $gCh. 17.$tProteases : targets of tumor invasion and metastasis /$rChristopher S. Foster and Christine Gosden -- $gCh. 18.$tAngiogenesis and angiogenesis inhibitors : applications in adenocarcinoma of the prostate /$rEdwin M. Posadas and William L. Dahut -- $gCh. 19.$tCell adhesion molecules in prostate cancer /$rKenneth A. Iczkowski and Christopher S. Foster -- $gCh. 20.$tCell survival, apoptosis, and proapoptotic therapies /$rHelgi van de Velde, Jeffrey S. Ross and Michel Janicot -- $gCh. 21.$tOncogenes /$rJoanne Edwards and John M. S. Bartlett -- $gCh. 22.$tp53 and tumor suppressor genes in prostate cancer /$rJeffrey S. Ross, Andre M. Oliveira, Jonathan A. Fletcher, Scott E. Eggener and Carlos Cordon-Cardo -- $gCh. 23.$tUbiquitin pathway and proteasome inhibitors /$rHelgi van de Velde and Jeffrey S. Ross -- $gCh. 24.$tSignificance of DNA methylation in prostate cancer initiation and progression /$rChristopher S. Foster and Samantha J. Ireland -- $gCh. 25.$tBioinformatics, computational biology, and morphometrics /$rOlivier Saidi and David A. Verbel -- $gCh. 26.$tProstate-specific membrane antigen and other cell surface protein targets for antibody-based therapeutics and immunotherapy in prostate cancer /$rJeffrey S. Ross, Karen E. Gray, Iain Webb, Gary S. Gray, Mark Rolfe, David P. Schenkein, David M. Nanus, Mathew I. Milowski and Neil H. Bander -- $gCh. 27.$tGene therapy and immunotherapy for prostate cancer /$rLaura K. Aguilar, Douglas J. Jolly and Estuardo Aguilar-Cordova -- $gCh. 28.$tPharmacogenomics and pharmacogenetics in prostate cancer /$rJeffrey S. Ross, W. Fraser Symmans, Lajos Pusztai and Gabriel N. Hortobagyi -- $gCh. 29.$tFunctional and molecular imaging of prostate cancer /$rNeeta Pandit-Taskar and Chaitanya R. Divgi -- $gCh. 30.$tEvaluation and assessment of molecular markers and their translation into clinical practice /$rMichael W. Kattan -- $gCh. 31.$tRegulatory aspects and implications of molecular testing in the United States /$rRobert G. Pietrusko.
650 0 $aProstate$xCancer$xMolecular aspects.$0http://id.loc.gov/authorities/subjects/sh2010010129
650 12 $aProstatic Neoplasms.$0https://id.nlm.nih.gov/mesh/D011471
700 1 $aRoss, Jeffrey S.$q(Jeffrey Stuart),$d1945-$0http://id.loc.gov/authorities/names/n95802560
700 1 $aFoster, Christopher.$0http://id.loc.gov/authorities/names/n94801770
856 41 $3Table of contents only$uhttp://www.loc.gov/catdir/toc/ecip0616/2006021436.html
852 00 $boff,hsl$hRC280.P7$iM65 2007 Q